-
Posted by
Two Blokes April 23, 2025 -
Filed in
Stock
-
16 views
In recent months, Medtronic has soundly outperformed the S&P 500 index. The company's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Medtronic's interest coverage and net debt to EBITDA ratios are robust.
